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Inﬂuenza is a major cause of death in the over 65s. Increased susceptibility to infection and
reduced response to vaccination are due to immunosenscence in combination with medical
history and lifestyle factors. Age-related alterations in the composition of the gut microbiota
have a direct impact on the immune system and it is proposed that modulation of the gut
microbiota using pre- and probiotics could offer an opportunity to improve immune
responses to infections and vaccination in older people. There is growing evidence that pro-
biotics have immunomodulatory properties, which to some extent are strain-dependent, and
are strongly inﬂuenced by ageing. Randomised controlled trials suggest that probiotics may
reduce the incidence and/or severity of respiratory infections, although there is limited data
on older people. A small number of studies have examined the potential adjuvant effects
of selected probiotics for vaccination against inﬂuenza; however, the data is inconsistent,
particularly in older people. This review describes the impact of age-related changes in
the gut on the immune response to respiratory infections and evaluates whether restoration
of gut microbial homoeostasis by probiotics offers an opportunity to modulate the outcome
of respiratory infections and vaccination against inﬂuenza in older people. Although there is
promising evidence for effects of probiotics on human health, there is a lack of consistent
data, perhaps partly due to strain-speciﬁc differences and an inﬂuence of the age of the
host. Further research is critical in evaluating the potential use of probiotics in respiratory
infections and vaccination in the ageing population.
Ageing: Immunity: Inﬂuenza: Probiotics
Respiratory infections are a leading cause of mortality
and morbidity in elderly people. Increased susceptibility
to infections is inﬂuenced by many factors, including
immunosenescence, nutritional status, poor hygiene
and living conditions, medical history, medication
use and stress. Reduced biodiversity, compromised stab-
ility and larger inter-individual variation in the gut
microbiota are also commonly reported to be associated
with ageing(1,2). This review examines how age-related
changes in the gut can impact on the immune system,
describes evidence suggesting that the gut microbiota
inﬂuences the immune response to respiratory infections
and evaluates whether restoration of gut microbial
homoeostasis by probiotics offers an opportunity to
modulate the outcome of respiratory infections and vac-
cination against inﬂuenza in older people.
Inﬂuence of ageing on the gut microbiota composition
Reduced biodiversity, compromised stability and larger
inter-individual variation in the gut microbiota have
become widely recognised as a feature of ageing(1–3). A re-
duction in total gene counts in faecal samples from 178
elderly subjects in long-term care compared with those
in the community illustrates the reduction in gut
microbiota biodiversity, which is associated with frailty,
morbidity and poor nutritional status in elderly sub-
jects(1). Also commonly reported is an age-related increase
in facultative anaerobes, including streptococci, staphylo-
cocci, enterococci and enterobacteria(4–7). These are
sometimes referred to as ‘pathobionts’; bacteria, which
are present at low concentrations in the healthy gut micro-
biota, but thrive in inﬂamed conditions and actively pro-
mote the inﬂammation by producing inﬂammatory
stimuli(7). It has been suggested that reduced intestinal
motility contributes to a compromise in the homoeostatic
equilibrium between the gut microbiota and the host im-
mune system in older people(2). However, the relationship
may be reciprocal, since impairment of the gut-associated
lymphoid tissue resulting in reduced production of
secretory IgA, α-defensins, antimicrobial peptides
and mucus may lead to failure to control the resident
microbiota, facilitating dysregulated growth(2).
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Age-related alterations in the composition of the gut
microbiota can inﬂuence health through a number of
mechanisms. Reduced biodiversity may result in
increased colonisation of toxin-producing Clostridium
difﬁcile, a major nosocomial complication affecting
older people(8,9). Excessive endotoxin production in the
gut can promote inﬂammation(10) and a decrease in
butyrate-producing bacterial groups may impair epi-
thelial integrity and remove the protective, trophic and
anti-inﬂammatory effects of butyrate from the colonic
epithelium(11–13).
The ageing immune system
The term ‘immunosenescence’ describes a loss of diver-
sity in the T cell repertoire and senescence or unrespon-
siveness of oligoclonal T cells, resulting in poor
antigen-speciﬁc cellular responses, skewing of immune
effector pathways and ultimately, poor resistance to in-
fection and response to vaccination(14). Degeneration of
the thymus, the site of T cell maturation, is a hallmark
of ageing; by age 50–55 years, the thymus is reduced to
approximately 10% of its original capacity and by age
70 years, thymic output of naïve T cells is virtually ab-
sent(14). However, the number of circulating T cells in
older people remains constant because of homoeostatic
proliferation of both naïve and memory T cells, much
of which is antigen-independent. Thymic involution,
combined with increased homoeostatic proliferation
and expansion of the memory compartment, dramati-
cally reduce T cell receptor diversity. In addition, re-
peated antigen exposure (for example, chronic antigenic
stimulation by persistent Herpes viruses), proliferation
of T cells and telomere shortening lead to replicative sen-
escence and as a result, dysfunctional cells increasingly
ﬁll the immunological space. Since a diverse T cell reper-
toire is essential for an effective immune response to new
infections and to immunisation, older individuals face a
signiﬁcant challenge in dealing with both(15,16). It is
well established that ageing is associated with an
increased susceptibility to infections(17) and that vaccines
are considerably less effective in older people(16,18,19),
presenting a major public health challenge.
Prolonged exposure to TNF, and perhaps other
inﬂammatory cytokines, promotes immunosenescence;
indeed young individuals with chronic inﬂammatory dis-
ease exhibit premature immunosenescence, telomere
shortening and reduced thymic output (reviewed in(14)).
The term ‘inﬂamm-ageing’ has been coined to describe
the now well-recognised progressive increase in chronic
inﬂammation associated with ageing. Triggers include
microbial components, tissue damage and metabolic
stress, which activate inﬂammasome pathways and lead
to the production of inﬂammatory cytokines and chemo-
kines, acute phase proteins and other inﬂammatory med-
iators (Fig. 1)(20). A number of factors have been
identiﬁed to modify inﬂamm-ageing, including diet and
the gut microbiota (Fig. 1)(20). However, paradoxically,
a shift towards a more anti-inﬂammatory proﬁle is not
necessarily beneﬁcial, since up-regulation of IL-10
production suppresses interferon γ production and the
expression of co-stimulatory molecules on antigen-
presenting dendritic cells (DC)(21). This results in a
decrease in the interferon γ:IL-10 ratio, which is asso-
ciated with impaired clearance of the inﬂuenza virus
from infected lung tissue and poor response to
vaccination(21).
Respiratory infections and response to inﬂuenza
vaccination in older people
Older people experience more frequent and severe respir-
atory infections and are at higher risk of associated com-
plications, such as pneumonia(22). As a result, there is
greater morbidity resulting from respiratory infections
in elderly individuals, and inﬂuenza is a major cause
of death in the over 65s(21,22). The efﬁcacy of inﬂuenza
vaccination is also signiﬁcantly impaired by ageing; it
is estimated that inﬂuenza vaccination protects only
17–53% of elderly individuals compared with 70–90%
of young(19,23). A direct relationship between poor vacci-
nation and immunosenescence is illustrated by the fact
that loss of CD28 (an important co-stimulatory molecule
on T cells) is one of the most well-recognised features of
immunosenescence and is correlated with a poor re-
sponse to vaccination(24–26).
Probiotics, ageing and immunity
Probiotics are deﬁned as ‘live microbial feed ingredients
that, when ingested in sufﬁcient quantities, exert health
beneﬁts on the consumer’(27). Most probiotics consist of
lactobacilli or biﬁdobacteria, but an increase in levels
of these bacteria in the gut is not necessarily a health
beneﬁt in itself and other parameters need to be con-
sidered. The same applies to prebiotics, deﬁned as ‘selec-
tively fermented ingredients that allow speciﬁc changes,
both in the composition and/or activity in the gastro-
intestinal microﬂora that confers beneﬁts upon host well-
being and health’(28) and synbiotics (a combination of the
two); simply altering numbers of particular bacterial
groups is not necessarily considered sufﬁcient evidence
for a health beneﬁt. However, there is some evidence
for beneﬁcial effects of probiotics on bowel function, in-
cluding infection- and antibiotic-associated diarrhoea(29),
on respiratory infection (see later) and on immune func-
tion(3,30). Claims relating to positive effects of probiotics
on immune function have been difﬁcult to substantiate
because many of the immunological markers employed
do not in themselves indicate a beneﬁcial physiological
effect(31). Moreover, there is a degree of redundancy
within the immune system, such that a reduction in the
functional capacity of one component may be compen-
sated for by another(31). Nevertheless, there is growing
evidence that probiotics have immunomodulatory
properties and that these properties of probiotics are
strain-dependent(32–41). For example, there is consistent
evidence that a number of probiotics enhance natural
killer (NK) cell activity in vitro(40–43) and there is some
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supportive evidence that this also occurs in vivo(44–46).
Probiotic strains whose cell walls are resistant to diges-
tion appear to be particularly potent enhancers of NK
activity; it is suggested that monocytes phagocytose the
probiotic bacteria and the insoluble cell wall components
induce the production of IL-12, which augments NK cell
activity(38,47). Animal studies suggest that this may ulti-
mately play a role in modulation of the risk of infection
(Fig. 2). For example, neonatal and infant mice adminis-
tered Lactobacillus casei Shirota by stomach tube for
3 weeks prior to infection with inﬂuenza demonstrated
a lower rate of accumulated symptoms, a greater survival
rate and lower titres of inﬂuenza in nasal washings taken
a few days after infection(48). These correlated with an in-
crease in NK cell activity and production of IL-12(48).
Probiotics have also been demonstrated to modulate
cytokine production in a strain-dependent manner.
Shida et al.(38) propose that probiotics fall into two
main categories: those which are ‘immunostimulatory’,
characterised by their ability to induce IL-12 and there-
fore to augment host defence via enhancement of NK
cell activity and T helper 1 pathways, and those which
are ‘immunoregulatory’, characterised by their ability
to induce IL-10 and the T regulatory pathway. In gen-
eral, lactobacilli tend to fall into the immunostimulatory
category, whereas biﬁdobacteria tend to fall in the immu-
noregulatory category(38,40). Kechaou et al.(49) screened
158 bacterial strains for their ability to modulate the
Fig. 1. (colour online) Overview of the triggers and modiﬁers of inﬂamm-ageing. ER, endoplasmic reticulum; TLR, Toll-like
receptor; TNFR, TNF receptor. Reproduced, with permission, from(20).
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Fig. 2. (colour online) Modulation of natural killer (NK) activity and
infection by probiotics. Enhancement of NK activity by probiotics
is suggested to require phagocytosis of the bacteria, resulting in
induction of cytokines, particularly IL-12. The mechanism involves
stimulation by insoluble bacterial cell wall components. Probiotics
with cells walls which are particularly resistant to digestion appear
to be better inducers of IL-12 and enhancers of NK activity.
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induction of IL-12 relative to IL-10 in TNFα-activated
HT-29 cells or peripheral blood mononuclear cells and
then selected one strain which was strongly
pro-inﬂammatory, one which was neutral, and one
which was strongly anti-inﬂammatory to test in a murine
model of inﬂuenza infection. The outcome was that the
most immunostimulatory strain provided the greatest
protection against weight loss and symptoms(49).
There is particular interest in the positive inﬂuence
of probiotics in older people, who are subject to alter-
ation in gut microﬂora composition, as well as immuno-
senescence. Although probiotics have been proposed
as prime candidates for ‘anti-immunosenescence’
therapy(50,51), and ‘have the potentiality to be involved
in the promotion of longevity’(2), there is limited infor-
mation regarding their inﬂuence on those aspects of
immunity, which are particularly susceptible to immuno-
senescence. A study by Moro-Garcia et al.(52) demon-
strated that Lactobacillus delbrueckii subsp. bulgaricus
8481 decreased the percentage of CD8+CD28− T cells
and increased the proportion of naïve T cells between
3 and 6 months compared with baseline in subjects
aged >65 years, although the mechanism is not clear.
However, there is some direct evidence that the immune
response to probiotics is signiﬁcantly inﬂuenced by
ageing. You and Yaqoob(41) demonstrated that periph-
eral blood mononuclear cell from older subjects (age
60–85 years) were more responsive to the immunoregula-
tory effects (IL-10 induction) of two strains of biﬁdobac-
teria than young subjects (age 18–30 years), whereas
peripheral blood mononuclear cell from young subjects
were more responsive to the immunostimulatory effects
(IL-12 induction) of two strains of lactobacilli (Fig. 3).
This suggests that the same probiotics might have differ-
ent effects on health outcomes in young and older sub-
jects. Further studies investigated the effects of the
same four probiotics, Biﬁdobacterium longum bv. infantis
CCUG 52486, B. longum SP 07/3, Lactobacillus rhamno-
sus GG and L. casei Shirota, on human DC function in
an allogeneic mixed leucocyte reaction model, using DC
and T cells from young and older donors in different
combinations. The study demonstrated that ageing
increased the responsiveness of DC to probiotics, but
this was not sufﬁcient to overcome the impact of immu-
nosenescence in the mixed leucocyte reaction, since pre-
treatment of young or old DC with lipopolysaccharide
or probiotics failed to enhance the proliferation of
T cells derived from older donors(53).
The choice of probiotic, particularly for older indivi-
duals, is a matter of debate. An interesting point of
view put forward by Dominguez-Bello et al.(54) is that
attempting to improve the gut microbiota composition
of older people by introducing probiotic strains charac-
teristic of a young microbiota is not necessarily the best
strategy, and it may be more appropriate to identify ‘suc-
cessfully aged’ donors of probiotic strains, which might
survive better in an older host and achieve a more suit-
able equilibrium with the resident microbiota. B. longum
bv. infantis CCUG 52486 is an example of a strain which
was identiﬁed to be present in particularly healthy sub-
jects aged >90 years(55). It has subsequently been
demonstrated to have particular ecological ﬁtness and
anti-pathogenic effects in vitro(56) and immunomodula-
tory effects which are strongly inﬂuenced by the age of
the host(41,53).
Probiotics and respiratory infections
Emerging evidence suggests that the resident gut micro-
biota plays an inﬂuential role in shaping antiviral
defences and modulating the outcome of viral infec-
tions(57). Evidence from animal models indicates that
germ-free mice are more susceptible to a number of infec-
tions, including inﬂuenza(58), and adult mice treated with
antibiotics under pathogen-free conditions before chal-
lenge with inﬂuenza have a critically impaired immune
response and delayed clearance of the virus compared
with those not treated with antibiotic(58). The suggested
mechanism is via Toll-like receptors and nod-like recep-
tor 3, which activate the nod-like receptor 3 inﬂamma-
some in the gut, eliciting indirect stimulation of
respiratory immunity(59,60). There may be additional, as
yet uncharacterised, functional links between mucosal
surfaces in the gut and respiratory system. Evidence
that gut-resident bacteria play a role in shaping immune
defences forms the basis for the hypothesis that pre- and
probiotics may modulate responses to infection or vacci-
nation. This hypothesis is supported by a number of ani-
mal studies, which demonstrate that several probiotic
strains prevent dissemination and improve clearance of
pathogen in the lung, and increase phagocytic and NK
activity in respiratory mononuclear cells(48,49,61–66).
Probiotic bacteria may reduce the incidence and/or
severity of respiratory infections in children(67), adults(68)
Fig. 3. Effect of probiotics on the IL-10:IL-12 ratio by human
peripheral blood mononuclear cells. S1, Biﬁdobacterium longum
bv. infantis CCUG52486; S2, B. longum SP 07/3; S3, Lactobacillus
rhamnosus GG; S4, Lactobacillus casei Shirota. Data are means
with standard errors for n 8 samples for each group and are
relative to a medium only control. There was a signiﬁcant effect of
age (P<0·001) and treatment (P<0·001) on the IL-10:IL-12 ratio
(two-way ANOVA). Signiﬁcant differences are denoted as aP<0·05,
bP<0·01 relative to the medium control for the same age group;
cP<0·05 relative to Lactobacillus rhamnosus GG for the same age
group; dP<0·05 relative to Lactobacillus casei Shirota for the same
age group; eP<0·05 relative to all the other strains for the same
age group (post-hoc t tests with Bonferroni correction). Signiﬁcant
age differences are denoted as *P<0·05, **P<0·01, ***P<0·001 for
the same treatment (one-way ANOVA followed by post-hoc t tests
with Bonferroni correction). Reproduced from(53) with permission.
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and in the elderly(69), although evidence is limited and
studies investigating prevention of common respiratory
illnesses have produced mixed results(59). A recent sys-
tematic review evaluated ten randomised controlled trials
with a total of 3451 participants investigating the effects
of probiotics for the prevention of upper respiratory tract
infections(70). The review concluded that there was a 42%
reduction in the number of participants experiencing at
least one episode of acute upper respiratory tract infec-
tion, a 47% reduction in the number of participants ex-
periencing three or more episodes of acute upper
respiratory tract infection and a 33% reduction in anti-
biotic usage(70). However, there was no effect on mean
duration of upper respiratory tract infection and there
was no data for older people, despite the fact that respir-
atory infections and associated secondary complications
are a signiﬁcant cause of death in individuals aged over
65 years. Furthermore, since ageing is associated with
reduced biodiversity and compromised stability of the
gut microbiota(2), older individuals may beneﬁt more
from intervention with probiotics.
Probiotics and the immune response to inﬂuenza
vaccination
Response to vaccination is increasingly being used as a
surrogate for the response to infection and can therefore
provide information on the immunomodulatory effects
of dietary components, including probiotics, in human
subjects(71). Four out of eight of the studies investigating
the impact of probiotics on responses to inﬂuenza vacci-
nation were conducted in healthy adults(72–75), while the
remaining four were conducted in elderly subjects(76–79);
three of these were conducted in institutionalised indivi-
duals(77–79) (Table 1). The largest of the trials conducted
in elderly subjects (n 362 and 375 on probiotic and
placebo, respectively) demonstrated no effect of
L. casei Shirota on respiratory infections, seroprotection,
seroconversion or mean antibody titres(79). However, a
much smaller trial (n 14–19 per group)(78) reported a
signiﬁcant increase in inﬂuenza-speciﬁc IgG and IgA in
subjects consuming L. plantarum CECT7315 and
CECT7316. Boge et al.,(77) conducted an intervention
trial of a probiotic drink containing Lactobacillus paraca-
sei ssp. paracasei (Actimel®) on the response to inﬂuenza
vaccination in healthy elderly volunteers (age >70 years).
This trial was conducted in two phases: a pilot study in
2005–2006 (probiotic/placebo consumed for 7 weeks),
followed by a conﬁrmatory study in 2006–2007 (probio-
tic/placebo consumed for 13 weeks), with the inactivated
inﬂuenza virus vaccine being administered during the
fourth week of intervention. H1N1 was the only vaccine
strain common to both phases of the study, with the
H3N2 and B strains being different between vaccination
seasons. In both phases of the trial, the probiotic group
exhibited higher virus-speciﬁc antibody titres post-
vaccination compared to the control group, although
these differences were only statistically signiﬁcant within
the conﬁrmatory phase(77). The intensity of the probiotic
effect was vaccine subtype-dependent, with the most
pronounced enhancement for the inﬂuenza virus H3N2
strain in the pilot and the B strain in the conﬁrmatory
study. Seroconversion rates within the probiotic group
in the conﬁrmatory phase were signiﬁcantly higher for
the B strain at 3, 6 and 9 weeks postvaccination com-
pared to the placebo group (P=0·02), but there was no
effect of the probiotic on seroconversion for the H1N1
or H3N2 strains(77). It is perhaps pertinent to note that
the B strain is known to show major human variability,
and the effects on this subtype therefore need to be inter-
preted with caution. Bunout et al.,(76) examined the ef-
fects of a complete nutritional formula containing a
range of nutrients and vitamins plus the probiotic
Lactobacillus paracasei (NCC 2461) and the prebiotic
fructo-oligosaccharide for 6 months on the response to
inﬂuenza and pneumococcal vaccines (given at 4 months)
in free-living Chilean subjects aged over 70 years. At
12 months there was a signiﬁcantly lower incidence
of infection, in particular, respiratory infection, in the
treatment group compared with the control group, but
there was no effect on antibody responses to either vac-
cine(76). A ﬁfth study in elderly subjects is not included
in Table 1 because of an unusual study design, which
makes the data very difﬁcult to interpret(80). In this
small study, twenty-seven elderly subjects consumed a
test food containing B. longum BB536 for 5 weeks,
with an inﬂuenza vaccination (2004/2005 campaign)
being given at 3 weeks. At 5 weeks, the subjects were
then randomised to either continue on the probiotic, or
to consume a placebo for a further 14 weeks. The rando-
misation was stratiﬁed for sex and H3N2 titres, but not
for overall protection, so that the proportion of subjects
with effective titres was 53·8% in the BB536 group and
28·6% in the placebo group(80). Although the paper
reports signiﬁcantly lower incidence of inﬂuenza and
fever in the probiotic group, the subject numbers are ex-
tremely small, and this data needs to be interpreted with
caution. Thus, it is too early to draw any conclusions re-
garding the potential inﬂuence of probiotics on the re-
sponse to inﬂuenza vaccination in elderly subjects;
more research is required.
In healthy adults, Biﬁdobacterium animalis ssp. lactis
(BB-12®) or Lactobacillus paracasei ssp. paracasei
(L. casei 431®) taken for 6 weeks increased inﬂuenza
vaccine-speciﬁc serum IgG and vaccine-speciﬁc salivary
sIgA titres after vaccination at 2 weeks in the 2008/
2009 campaign(75). There was no effect of either probiotic
on vaccine-speciﬁc serum IgA or IgM on plasma cyto-
kine concentrations, or on parameters of innate immun-
ity, although the authors acknowledge that sampling at
4 weeks after vaccination may have missed changes in
immune response to the vaccine(75). Lactobacillus GG
taken for 28 d immediately after receiving a nasally
administered trivalent live attenuated inﬂuenza vaccine
from the campaign of 2007/2008 signiﬁcantly increased
seroprotection (haemagglutinin inhibition antibody titre
=40) to the H3N2 virus strain, but not to the H1N1 or
B strain at day 28(74). However, at day 56 the rates of
seroconversion (at least a fourfold rise in HAI antibody
titre) were not signiﬁcantly different. French &
Penny(73) reported signiﬁcantly higher antibody titres to
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Table 1. Studies investigating the effects of probiotics on the response to inﬂuenza vaccination
Probiotic(s) used Vaccine(s) used Study design Outcomes Reference
Lactobacillus casei Shirota
(6·5×109 in 65ml fermented
milk product twice daily)
Parenteral attenuated trivalent
inﬂuenza vaccine for the campaign of
2007/2008
Healthy men & women >65 years from ﬁfty-three
nursing homes on probiotic (n 362) or placebo
(n 375) for 176d during winter 2007–2008.
Vaccination at 21d, sampling at days 1, 50, 176
No effect on respiratory infections
172 subjects seroprotected at baseline; no effect
of probiotic on seroprotection, seroconversion or
mean Ab titres
(79)
Lactobacillus plantarum
CECT7315 and CECT 7316
Parenteral attenuated trivalent
inﬂuenza vaccine for the Spanish
campaign of 2006/2007
Institutionalised elderly subjects aged 65–85 years
randomly assigned to 5×109 cfu/d (n 19) OR 5×
108cfu/d (n 14) L. plantarum CECT 7315/7316 (in a
1:1 ratio) in 20g powdered skim milk OR placebo
(20g skim milk; n 15). Intervention initiated 3
months after vaccination; duration 3months
Signiﬁcant increase in inﬂuenza-speciﬁc IgG
only in group receiving high dose.
Increase in inﬂuenza-speciﬁc IgA in both
probiotic groups
78
Biﬁdobacterium animalis ssp.
lactis (BB-12®) or Lactobacillus
paracasei ssp. paracasei
(L. casei 431®) 1×109/d
Parenteral attenuated trivalent
inﬂuenza vaccine for the campaign of
2008/2009
Healthy adults given probiotic (n 53 for BB-12®, n 56
for L. casei 431®) or placebo (n 102) for 6 weeks;
vaccination at week 2
Signiﬁcantly greater increase in vaccine-speciﬁc
IgG antibody titre in probiotic groups v. placebo
(P<0·001 for IgG1 and IgG3)
Signiﬁcantly greater mean-fold increases for
vaccine-speciﬁc secretory IgA antibody in saliva
in BB-12® group (P=0·035) and L. casei 431®
group (P=0·017) v. placebo group
(75)
Lactobacillus GG 1×1010cfu and
295mg prebiotic inulin twice
daily
Nasally administered attenuated
trivalent inﬂuenza vaccine for the
campaign of 2007/2008
Healthy adults given probiotic (n 21) or placebo (n 21)
for 28 d after vaccination
Lactobacillus GG signiﬁcantly increased
seroprotection rate to the H3N2 strain at day 28
(P=0·048), but not to the H1N1 or B strain
No effect on seroconversion rates at day 56
(74)
Lactobacillus fermentum VR1003 Parenteral inactivated trivalent
inﬂuenza vaccine 2006 (Australia)
Healthy adults randomised to 1×109cfu/d probiotic
capsules (n 21) or placebo (n 26). 6 weeks
intervention, initiated 2 weeks prior to vaccination
Signiﬁcantly higher median H1N1 titres in
probiotic group, but no differences for other
subunits
Average number of respiratory symptoms reduced
(2 v. 5 d)
(73)
Lactobacillus paracasei ssp.
paracasei (Actimel®)
1010cfu/100g bottle twice daily
Parenteral inactivated trivalent
inﬂuenza virus vaccine (2005–2006
campaign vaccine for pilot study and
2006–2007 for conﬁrmatory study)
Elderly subjects in nursing homes. Pilot study:
probiotic (n 44) or placebo (n 42) consumed for
7 weeks
Conﬁrmatory study: probiotic (n 113) or placebo
(n 109) consumed for 13 weeks. Vaccination after
4 weeks
Trend for higher virus-speciﬁc antibody titres
in probiotic v. control group
Signiﬁcantly greater seroconversion rate for B
strain in main study at 3, 6 and 9 weeks
post-vaccination in probiotic v. placebo group
(P=0·02)
(77)
Lactobacillus fermentum
(CECT5716) 1×1010cfu/d
Parenteral inactivated trivalent
inﬂuenza vaccine for the campaign
of 2004/2005
Healthy adults given probiotic (n 25) or placebo (n 25)
for 4 weeks; vaccination on day 14
Probiotic increased vaccine-speciﬁc IgA
antibodies post-vaccination (P<0·05)
Incidence of inﬂuenza-like illnesses for 5 months
post-vaccination lower in the probiotic v. placebo
group (P<0·05 for last month)
(72)
Lactobacills paracasei (NCC
2461) 1×109cfu and 6g
prebiotic fructo-oligosaccharide
as part of a daily nutritional
formula
Parenteral trivalent inﬂuenza vaccine
and pneumococcal vaccine
containing twenty-three serotypes
Elderly subjects (≥70 years) given either nutritional
formula containing a range of nutrients and
vitamins plus the probiotic NCC 2461 and prebiotic
for 6 months or no supplement; vaccination after
4 months
No effect on antibody response to vaccines
Signiﬁcantly lower incidence of infection after
12 months, in particular respiratory illnesses, in
treatment group v. controls (P=0·034)
(76)
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H1N1 following intervention with Lactobacillus fermen-
tum VRI 003 for 6 weeks in total (vaccination after
2 weeks), but there were no differences for other subunits.
The average number of days of respiratory symptoms
was reduced from 5 to 2d(73). Lactobacillus fermentum
CECT5716, taken for 4 weeks, signiﬁcantly increased
titres of inﬂuenza virus-speciﬁc plasma IgA (but not
IgM or IgG) to the inactivated trivalent inﬂuenza vaccine
for the vaccine campaign of 2004/2005, administered
2 weeks into the intervention(72). Additionally, the inci-
dence of inﬂuenza-like illnesses for 5 months post-
vaccination were lower in the probiotic group compared
to the control group(72). Overall, there is some evidence
for adjuvant effects of probiotics in inﬂuenza vacci-
nation, but this is currently limited, most of the studies
are very small, and there may be strain-speciﬁc differ-
ences which need to be considered(40,47). In selecting pro-
biotics with potential adjuvant activity speciﬁcally
targeted towards older individuals, Dominguez-Bello
et al.(54) suggest that ‘the healthy old rather than the
healthy young are the best donors of probiotic species
for old individuals’. This argues against the common per-
ception that modulating the microbiota composition of
an aged gut to resemble that of a younger individual
will be beneﬁcial for intestinal health and immunity.
Instead, it is suggested that the aim should be to establish
a new equilibrium with a suitably aged microbial com-
munity in an older human host(54).
Future perspective
In their recent review, Kau et al.(81) propose that ‘the
time is right and the need is great to understand better
the relationships between diet, nutritional status, the im-
mune system and microbial ecology in humans at differ-
ent stages of life.’ They suggest that a combination of
metagenomics methods for describing the gut micro-
biome and the use of gnotobiotics (rearing of animals
under germ-free conditions with subsequent exposure to
single species) represents a potentially powerful approach
to examine relationships between nutritional status and
gut microbial communities. It may also provide a mech-
anistic understanding of the inﬂuence of the gut micro-
biota on the immune system that could be used to
inform the design and execution of human studies. One
of the challenges in this area is that the effects of probio-
tics on human health may be strain-speciﬁc and, as this
review illustrates, dependent on the age of the host.
Hypothesis-led research is therefore critical in evaluating
the potential use of probiotics in respiratory infections
and vaccination in the ageing population.
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